Apatinib in combination with docetaxel and S‐1 chemotherapy as first‐line treatment for metastatic gastric cancer
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70351 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Ling Xia und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center, Zhongnan Hospital, Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Pyridines, Docetaxel, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Hubei Province "Chutian Scholar Program" for Medical and Health Talent Development Project.
Themen: Onkologische Pflege
Abstract (Originalsprache)
This study aimed to evaluate the efficacy and safety of apatinib, an oral VEGFR2 tyrosine kinase inhibitor, combined with docetaxel and S‐1 (DS) as first‐line therapy for metastatic gastric cancer (mGC) patients whose median overall survival (mOS) with chemotherapy typically remains below 12 months. In this prospective, multi‐center, single‐arm phase II trial (NCT03154983), patients received docetaxel (75 mg/m 2 , day 1) and S‐1 (body surface area‐based dosing, days 1–14) every 3 weeks, plus daily apatinib (500 mg), for up to 6 planned cycles. 45 patients were enrolled, with a median follow‐up time of 12.4 months. Median progression‐free survival (PFS) and overall survival (OS) were 7.6 months (95% CI: 5.8%–9.4%) and 12.4 months (95% CI: 9.3%–15.5%), respectively in the full analysis set. Patients completing ≥4 cycles achieved a better mOS of 14.5 months (95% CI: 12.0%–17.1%). The objective response rate (ORR) and disease control rate (DCR) were 62.2% (95% CI, 46.5%–76.2%) and 82.2% (95% CI, 67.9%–92.0%), respectively, including one complete response (CR). Grade 3–4 treatment‐related adverse events occurred in 48.9% of patients, most commonly oral mucositis and neutropenia. These findings support apatinib plus DS as a promising biomarker‐independent first‐line treatment strategy for mGC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation and Medical Oncology, Hubei Cancer Clinical Study Center, Zhongnan Hospital, Wuhan University, Wuhan, China.
- Hubei Key Laboratory of Tumor Biological Behavior, Wuhan, China.
- Huangshi Central Hospital of Hubei Province, Huangshi, China.
- Department of Abdominal and Pelvic Medical Oncology, The First People's Hospital of Tianmen City, Affiliated Hospital of Hubei Technology College, Tianmen, China.
- Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Oncology, Xiang Yang Central Hospital, Hubei University of Art and Science, Xiangyang, China.
ORCID-Profile: Yu Gao, Hui Xu, Wei Gong, Fuxiang Zhou
Förderung
- Hubei Province "Chutian Scholar Program" for Medical and Health Talent Development Project
Zitieren
APA
Xia, L., Gao, Y., Yang, L., Jiang, H., Gong, J., Wang, Q., Wu, H., Wang, Y., Xu, H., Wang, W., He, L., Chen, W., Gong, W., Yu, X., Peng, J., Dai, J., & Zhou, F. (2026). Apatinib in combination with docetaxel and S‐1 chemotherapy as first‐line treatment for metastatic gastric cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70351
Vancouver
Xia L, Gao Y, Yang L, Jiang H, Gong J, Wang Q, et al. Apatinib in combination with docetaxel and S‐1 chemotherapy as first‐line treatment for metastatic gastric cancer. International Journal of Cancer. 2026. doi:10.1002/ijc.70351
BibTeX
@article{Xia2026,
author = {Xia, Ling and Gao, Yu and Yang, Lei and Jiang, Huangang and Gong, Jun and Wang, Qingyun and Wu, Han and Wang, You and Xu, Hui and Wang, Wenbo and He, Lilin and Chen, Weidong and Gong, Wei and Yu, Xiongjie and Peng, Jin and Dai, Jing and Zhou, Fuxiang},
title = {Apatinib in combination with docetaxel and S‐1 chemotherapy as first‐line treatment for metastatic gastric cancer},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70351}
}
EUVIMED